JNJ - Johnson & Johnson
129.54 0.00 (0.00%)
After hours: 5:31PM EDT
| Previous Close | 130.78 |
| Open | 130.11 |
| Bid | 129.54 x 1200 |
| Ask | 130.47 x 800 |
| Day's Range | 129.33 - 130.75 |
| 52 Week Range | 121.00 - 148.99 |
| Volume | 4,498,079 |
| Avg. Volume | 7,405,100 |
| Market Cap | 341.878B |
| Beta (3Y Monthly) | 0.73 |
| PE Ratio (TTM) | 21.51 |
| EPS (TTM) | 6.02 |
| Earnings Date | Oct 15, 2019 |
| Forward Dividend & Yield | 3.80 (2.91%) |
| Ex-Dividend Date | 2019-08-26 |
| 1y Target Est | 149.35 |
- PR Newswire
S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels
- Q2 2019 share repurchases were $164.5 billion - 20.1% lower than Q1 2019, 13.7% lower than Q2 2018, and 26.2% lower than the record Q4 2018. - Apple continues to lead, spending $18.2 billion - down from ...
- Benzinga
Purdue Pharma Files For Bankruptcy: What You Need To Know
Each day, over 130 people in the U.S. die from opioid overdoses, according to the National Institute on Drug Abuse. Purdue is facing a slew of lawsuits filed by several states, counties and cities over its role in the opioid crisis. The bankruptcy filing follows an agreement the company reached in principle for settling U.S. opioid litigation with 24 state attorneys general.
- Zacks
AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure
The FDA assigns a Fast Track status to AstraZeneca's (AZN) Farxiga to reduce the risk of cardiovascular death or worsening of heart failure in adult patients with HFrEF and HFpEF.
- Zacks
Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study
Amgen's (AMGN) phase III study on Kyprolis in combination with dexamethasone and J&J's Darzalex meets the goal of progression-free survival for treating relapsed or refractory multiple myeloma.
- Financial Times
CMR Surgical hits £1bn valuation as it rolls out robots for surgery
CMR Surgical, a five-year-old medical robotics company based in Cambridge, has raised £195m in a funding round that pushed the value of the company to more than £1bn ahead of the launch of its first product. The Series C financing — the largest in Europe‘s medical technology sector, according to CMR — will “fully fund the global commercialisation of the business”, said Martin Frost, chief executive. Versius is designed to provide surgeons with multiple robotic arms to carry out a range of keyhole or minimal access procedures.
- Reuters
UPDATE 1-OxyContin maker Purdue Pharma files for bankruptcy protection
OxyContin maker Purdue Pharma LP filed for bankruptcy protection Sunday night, succumbing to pressure from more than 2,600 lawsuits alleging the company helped fuel the deadly U.S. opioid epidemic. Purdue's board met Sunday evening to approve the long-expected bankruptcy filing, which the company is pursuing to restructure under terms of a proposal to settle the widespread litigation. Purdue, which filed for Chapter 11 protection in a federal bankruptcy court in White Plains, New York, reached a tentative deal to resolve lawsuits with 24 states and five U.S. territories, as well as lead lawyers for more than 2,000 cities, counties and other plaintiffs, the company said.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From GSK, PFE & Others
Glaxo's (GSK) Nucala gets FDA nod for use in kids. Pfizer (PFE), Allergan (AGN) & Roche (RHHBY) give regular pipeline/regulatory updates.
- GuruFocus.com
6 Stocks With Low Price-Sales Ratios
Johnson & Johnson tops the list Continue reading...
- American City Business Journals
Alabama hospitals file suit against opioid manufacturers and distributors
A group of 21 Alabama hospitals, including UAB Health System affiliates Medical West and The Healthcare Authority for Baptist Health, Brookwood Baptist Medical Center, Princeton Baptist Medical Center, Walker Baptist Medical Center, Shelby Baptist Medical and Grandview Medical Center, has filed suit in Conecuh County Circuit Court against the manufacturers, distributors and retailers of opioid-based drugs. "Our hospitals, along with many others, have been on the front lines of treating patients for this epidemic and continue to incur significant financial harm and consequences as a result," a statement from Brookwood Baptist Health said. "These dollars were spent to the detriment of other health-related programs and benefits for the people in the community we serve." UAB and Grandview declined to comment further on pending litigation.
- Zacks
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
J&J (JNJ) announces superiority of its multiple sclerosis candidate, ponesimod compared to Sanofi's Aubagio in patients with relapsing form of the disease.
- InvestorPlace
9 Best Dividend Stocks to Buy for Every Investor
[Editor's note: "9 Best Dividend Stocks to Buy for Every Investor" was previously published in July 2019. It has since been updated to include the most relevant information available.]No matter where we are in the economic cycle, it's always good to remind ourselves of what worked and what didn't. In 2017, Wall Street forecast a rough yea,r but quite the opposite happened. Benchmark indices hit all-time records, while investors ended up being upbeat about most sectors.In 2018, the long-running bull market took a breather as investors switched from risk-on to risk-off.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThis year so far has only been a little forgiving and that might not last, which is why I recommend that investors get selective. Fortunately, with dividend stocks, investors don't have to feel pressured to always pick winners. * 10 Battered Tech Stocks to Buy Now Although picking high-flying growth companies is a sexier endeavor, they aren't always the smartest stocks to buy. With passive-income yielding firms, you get the potential to make capital gains and obtain residual payouts to bolster your position. During a down period, dividends can also help you ride out the storm.But don't mistake benefiting from these yields as "boring" strategies. As with any asset class, you can dial up the risk for the chance of greater rewards.. No one knows your investment style better than you!The following ideas are broken down into three sections: stable, mid-level and high-yield (speculative). Each section has something to offer, depending on how much risk you're willing to take. Johnson & Johnson (JNJ)Current Dividend Yield: 2.9%If you love stable dividend stocks, Johnson & Johnson (NYSE:JNJ) is one of the best dividend stocks to buy. It is the powerhouse brand of powerhouse brands. Better yet, JNJ is levered toward the ultimate in non-cyclical industries: healthcare. Selling consumer-level products, pharmaceuticals, and medical devices, JNJ is one of the most respected companies in the world.Source: Shutterstock Currently, Johnson & Johnson's dividend yield is 2.9%. But what people may not immediately appreciate is that JNJ can also surprise people in the capital markets. For instance, since mid-2015, shares are up nearly 40%.Critically for conservative investors, JNJ rarely loses. Between 1970 to the end of 2018, annual returns average almost 15%. Moreover, JNJ only hit red ink 14 times, meaning that 72% of the time, you can expect shares to win.In our business, that's as close to a sure thing as you're gonna get! Wells Fargo (WFC)Current Dividend Yield: 4.22%I'll admit that I wasn't thrilled about putting Wells Fargo & Co (NYSE:WFC) into my dividend stocks to buy list. You'll recall that WFC was embroiled in a major controversy that shocked the entire financial and business community. Essentially, the banking giant admitted to creating more than two million fake accounts to meet ambitious sales targets.Source: Shutterstock It made me sick and I'm not the only one. But eventually, people get over this stuff, perhaps resigned to the fact that the major conglomerates always win. I even made the argument that Equifax Inc (NYSE:EFX) -- yes, that Equifax -- would be forgiven. * 10 Battered Tech Stocks to Buy Now As cynical as it may sound, what good will being angry do for any of us? Today Equifax is just around a few percent off its pre-scandal highs, and Wells Fargo is now above its pre-scandal highs.It stinks that the ultra-rich get away with bloody murder. From a financial perspective, though, WFC is an opportunity. It's slowly making recovery inroads. Most important, WFC spits out the biggest dividend yield among the "big four" at more than 4%. That may be the price of forgiveness! Exxon Mobil (XOM)Current Dividend Yield: 4.84%Again, on the surface level, Exxon Mobil (NYSE:XOM) is a strange name to put on a "best dividend stocks" list. Energy is hardly the most consistent sector. More to the point, XOM has been on the wrong end of a market shake-up. Since the oil collapse of 2014, XOM has at best been treading water against prior highs.Source: Shutterstock But the flip side to this bearish argument is that in practical ways, energy is the most consistent sector possible. When people hit the switch, they expect the lights to turn on. Similarly, when they go to the gasoline station, they expect to fill their tanks. Without XOM and its ilk, none of these things would occur. A societal breakdown could commence.In all seriousness, investors should be encouraged by Exxon Mobil's response to the oil market downturn. They and the remaining survivors have revamped their operations and rid themselves of unproductive assets. Today, XOM and the oil community are leaner, meaner, and better prepared for whatever lies ahead.In other words, XOM has proven its resilience, adding another 5.5% since the beginning of the year. As a conservative investor, you can buy that 4.8% yield with confidence. Duke Energy (DUK)Current Dividend Yield: 4%If you're a real numbers person, you'll want to pay attention to Duke Energy (NYSE:DUK). Based on a quantitative model that our own Louis Navellier developed, DUK is one of the best dividend stocks to buy. Mixing in commonly-used metrics (ie. earnings momentum) as well propriety methods, DUK appears primed for a stellar new year.Source: Shutterstock I prefer to keep it simple if there's no real need to complicate things. Here's what I'm looking at: Since the tech bubble and the 2008 financial crisis, DUK has steadily rewarded investors with few hiccups. This year, DUK is set to return more than 13% if its yield and price stay at their current levels for the rest of 2019.All indications suggest that Duke Energy can keep the good times flowing into next year. As it stands, the company is the seventh-largest electric utility company in the U.S. Furthermore, management has retired many of its coal power plants, focusing instead on natural gas and cleaner energy sources. * 10 Battered Tech Stocks to Buy Now Currently, DUK stock yields 4%. Although slightly riskier than your conservative dividend play, Duke Energy has the right balance between stability and income. AT&T (T)Current Dividend Yield: 5.3%I have to say that AT&T Inc. (NYSE:T) disappointed me this year in the capital markets. Typically, AT&T is like clockwork, more often than not, you know what you're getting. This year was the anomaly.Source: Mike Mozart via FlickrT stock dropped like a rock last year but managed to recover its losses and then some, adding nearly 36% so far this year.Keep in mind that between 1984 through 2016, AT&T's annual returns average more than 13%. During this time, T stock has only lost eight times out of 33. AT&T has been a winner almost 75% of the time.Like the aforementioned JNJ, at this rate, T stock is practically a sure thing. The only difference is the reward. AT&T offers a whopping 5.3% dividend yield! Welltower Inc (WELL)Current Dividend Yield: 3.97%It's always a little amusing to see a generation come of age. The news flash that everyone else knows instinctively is that time stops for no one; "youth is wasted on the young."Source: sima dimitric via FlickrWith that harsh reality in mind, I bring to you Welltower (NYSE:WELL). WELL stock is a real estate investment trust specializing in senior care and facilities. Even if you're one of the young millennials who see no use for Welltower, you still might put your parents into one of their centers. * 10 Battered Tech Stocks to Buy Now Joking aside, I can think of no other business where revenues are virtually guaranteed, save for a funeral home. Although Welltower's market performance has been a little choppy, in the long haul, Welltower has been a steady investment.Of course, we can't forget the dividend yields, which for WELL stands at nearly 4%. Blackstone Group (BX)Current Dividend Yield: 4.1%Moving on to the speculative side of dividend stocks, we have Blackstone Group (NYSE:BX). If you were to simply assess BX based on this year's performance alone, Blackstone wouldn't seem at all risky. In 2019, BX has gained 69% (excluding dividends) making it a solid performer.Source: Shutterstock Typically, strong capital returns and high yields don't go together. With a dividend yield of 4%, Blackstone's passive income is right around the same as an average mutual fund. So what gives?Let's just say that BX will probably never make the list of best "feel good" stocks. The financial firm has been involved in a number of controversies, ranging from scandalous real-estate practices to shadow banking. It's really one of those profit-at-all-costs kind of companies. But hey, who said Wall Street was a friendly place? Kimco Realty Corp (KIM)Current Dividend Yield: 5.55%I will tell you straight up that anything involving brick-and-mortar retail is a risky game. Earlier this year, I cautioned my readers about investing in retail REITs. With overall declining foot-traffic, the physical retail space doesn't have the appeal it once did. Of course, the most important factor is e-commerce. Why sit in traffic and wait in lines when you can shop conveniently at Amazon (NASDAQ:AMZN)?Source: Shutterstock The flip side to this argument is that there are some retail sectors that Amazon has trouble ousting. For instance, most people find it more convenient to size their clothing at a physical apparel shop than guessing online.In addition, some store brands offer better pricing or a better experience than Amazon. Think Wal-Mart (NYSE:WMT), Costco (NASDAQ:COST) and Best Buy (NYSE:BBY). * 10 Battered Tech Stocks to Buy Now A retail REIT that focuses on strong brands just might have a chance, hence Kimco (NYSE:KIM). KIM features multiple properties running highly demanded store brands. Moreover, a good chunk of their properties are located in lucrative markets.Will it be enough to overcome the risk to the entire sector? I'm not so sure, which helps explain Kimco's 5.55% dividend yield. If you're a believer, KIM stock gives you a solid opportunity. Sotherly Hotels Inc (SOHO)Current Dividend Yield: 7.77%Thanks to the abundance of consumer-level technologies, traditional industries face obsolescence. A decade ago, if you needed to go to the airport, you essentially had to call a cab. Now, with ride-sharing apps like Uber or Lyft, you can request a similar service conveniently through your smartphone.Source: Anders Jilden via UnsplashA similar upheaval may occur in the hotel industry, thanks to apps like Airbnb. To survive in this rough-and-tumble sector, you need a fresh approach. Sotherly Hotels (NASDAQ:SOHO) just might have the magic formula. Centered largely in the southern region of the U.S., SOHO provides an authentic, unique experience for its guests.Apparently, most millennials want brands to be more authentic, and that fits SOHO to a T. Visit any of their locations, and you feel like a welcomed member of a community, not some room number. Plus, former NFL star Herschel Walker sits on the board of directors. That's just downright awesome!But will any of this matter for investors? Again, it's a tough call given so many changes in the hospitality and services sector. Still, with a 7.77% dividend yield, SOHO is worth a second look.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Battered Tech Stocks to Buy Now * 7 Strong-Buy Stocks Hedge Funds Are Buying Now * The 7 Best Penny Stocks to Buy The post 9 Best Dividend Stocks to Buy for Every Investor appeared first on InvestorPlace.
- Zacks
Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $131.17, moving +1.25% from the previous trading session.
- Zacks
Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up
Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.
- Zacks
Lexicon (LXRX) Settles With Sanofi for $260M, Shares Rally
Lexicon Pharmaceuticals (LXRX) settles with Sanofi related to termination of their alliance for development of Zynquista in type I and type II diabetes.
- Zacks
Theravance Announces Positive Early Data on JAK Inhibitor
Theravance's (TBPH) investigational JAK inhibitor TD-8236 demonstrates favorable results from a phase I study for treating inflammatory lung diseases.
- InvestorPlace
10 Healthcare Stocks to Buy Despite the Headlines
The past several weeks have been raucous ones for all stocks, but particularly wild ones for healthcare stocks. Not only is the future of the nation's healthcare market in flux, drug companies are facing an inordinate degree of litigation, and biopharma names have dished out plenty of R&D updates … some good, some bad.By and large, the bearish market-wide tide and the weakness healthcare stocks have suffered has become something of an opportunity. A handful of these names have become bargains and are ripe for recoveries. * 10 Stocks to Sell in Market-Cursed September To that end, here's a rundown of ten healthcare stocks to buy, even if they're surrounded by bad news and grim headlines. Some are familiar, and others are not. All of them, however, arguably boast more potential than risk at this time, even if not all of them have yet to reach their worst-case-scenario price.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (JNJ)Source: Sundry Photography / Shutterstock.com Johnson & Johnson (NYSE:JNJ) has arguably faced the worst and most alarming headlines of late, facing not one but two major legal battles.The first one of course is its liability linked to asbestos contained in its talcum powder sold under the brand name Johnson & Johnson. The other? Some states' attorneys general are suggesting J&J was culpable for what's turned into a nationwide opioid addiction epidemic. A closer inspection of both matters reveals the ultimate liability for both may not be as dire as is currently believed.Though the state of Oklahoma recently won a case that will fine Johnson & Johnson $572 million for allowing opioid abuse to become a "public nuisance," that figure was smaller than shareholders had feared, and may point to similarly small figures in other state-level cases.As for its talcum powder woes, the company is prevailing in some state courts, and losing in others. With the exception of one case in California, the awards granted in cases it has lost have been relatively modest. AbbVie (ABBV)Source: Piotr Swat/Shutterstock AbbVie (NYSE:ABBV) shares are down nearly 50% from their early 2018 high, reaching another multi-month low in August.The underpinnings for that weakness aren't difficult to deduce. Aside from an increasingly tough battle to defend its patents on breadwinner drug Humira, the decision to acquire Allergan (NYSE:AGN) hasn't been a particularly popular one with shareholders.ABBV stock owners have also been disappointed by a couple of major busts on the R&D front. The company's work in turning Rova-T into a successful lung cancer treatment, for instance, was thrown away when AbbVie ended phase 3 trials after it failed to create meaningful results. * 7 "Boring" Stocks With Exciting Prospects The punishment, so to speak, hasn't fit the crime though. AbbVie now quietly rates as one of the top healthcare stocks to buy at its now greatly-lowered price thanks to a dividend yield of 6.44% that's reasonably well protected, and a forward-looking P/E of only 7.. CVS Health (CVS)Source: Shutterstock Admittedly, it remains unclear which sliver of the healthcare market will be the one to bear the brunt of any cost-cutting reform. Hospitals and insurers are just as targeted as pharmacy names like CVS Health (NYSE:CVS), which is a key part of the reason CVS stock has been nearly cut in half since the middle of 2015.That doubt is rooted in a paradigm shift that isn't likely to happen, however, or at least not as abruptly as some are fearing.Case in point: Just days after announcing plans to eliminate the rebate enjoyed by pharmacies and pharmacy benefits managers, President Donald Trump backpedaled. Although it's not clear where the pressure for the reversal came from, clearly someone is in the industry's corner.In the meantime, CVS is preparing for all contingencies. It now owns health insurer Aetna and is tiptoeing into the medical device arena. In July the company announced it was beginning trials of an at-home kidney dialysis solution. Bausch Health Companies (BHC)Source: n4i Via FlickrYou may recognize the name as one that has specialized in eye care for a long time now. And Bausch -- Bausch + Lomb, to be precise -- certainly still makes contact lenses and eye-surgery products. This is not the Bausch Health Companies (NYSE:BHC) in question, however. While Bausch Health owns and operates Bausch + Lomb, the Bausch that has earned a spot on a list of healthcare stocks to buy is actually the company formerly known as Valeant Pharmaceuticals.That name will also ring a bell for most investors … although not a good one. That's the company that went on an aggressive acquisition spree, planning on buying specialty drugs to then mark their price up to unnecessarily expensive levels.In addition to public outcry, congress got involved, ultimately forcing then-CEO Michael Pearson out, and forcing new CEO Joseph Papa to rebuild everything the company is, and does. * 7 Best Stocks That Crushed It This Earnings Season Surprise! He's doing it. Though it's still erratic and somewhat unpredictable, sales are expected to grow 1.6% this year, and 3% next. It's not much, but it's enough to drive real earnings growth. Intercept Pharmaceuticals (ICPT)Source: Shutterstock Intercept Pharmaceuticals (NASDAQ:ICPT) isn't an easy name to own. Although the biopharma outfit is driving major sales growth with its chronic liver disease drug Ocaliva, the company's a one-trick pony that's still losing money. Last quarter's top line of $66.3 million -- mostly Ocaliva -- was up 53% year-over-year, but still let Intercept book an operating loss of $63.6 million and a total net loss of $71.4 million.In this case though, the company's fiscal trajectory against the backdrop of an obesity epidemic translates into a bright future. Intercept Pharmaceuticals is also working on a nonalcoholic steatohepatitis (NASH) drug that takes aim at what is expected to be the leading cause of liver failure by 2020. That under-served market could be worth $50 billion, if not more, leaving this company amazingly well-positioned for growth. Pfizer (PFE)Source: Manuel Esteban/Shutterstock Stripping out last month's 20% stumble, Pfizer (NYSE:PFE) has been a pretty good bet in recent years. Thing is, the aspects that have made PFE stock one of the best healthcare stocks to buy for a long while now are still in place. That is, a diverse portfolio that doesn't lean too much on any one drug. No one product accounts for more than 10% of the company's total revenue.The selloff, for the record, was spurred by the decision to sell its 'off patent' drug business operating as Upjohn to rival Mylan (NASDAQ:MYL). The downside of that exit appears to be fully priced in now though, and then some. * The 8 Worst Stocks to Buy Before the Trade Turmoil Cools Off In the meantime, a $500 million investment in a North Carolina manufacturing facility pushes the company deeper into gene therapy waters, which may offer more upside than existing business lines. PRA Health Sciences (PRAH)Source: Shutterstock When investors thinks of healthcare stocks, PRA Health Sciences (NASDAQ:PRAH) isn't a name that generally comes to mind. Indeed, most investors may have never even heard of it.The one who have heard of it, meanwhile, might be wishing they hadn't. Even with this year's choppy rebound effort, shares of the contract research organization are still down 19%.A bet against PRA Health Sciences hasn't been a particularly wise bet in the grand scheme of things. Contracted research is a key part of the future of healthcare, as outsourcing R&D becomes the more cost-effective solution.PRA Health has the numbers to prove it, too. This year's expected 6.4% revenue growth isn't jaw-dropping, but it's reliable, as will be next year's projected 8.4% top-line growth. Better still, that progress is driving even greater profit growth. Per-share profits are expected to reach $5.03 this year, up from last year's $4.28, and grow 13% to $5.68 per share next year. Alexion Pharmaceuticals (ALXN)Source: Shutterstock Last week, Alexion Pharmaceuticals (NASDAQ:ALXN) shares started what would end up becoming a 14% plunge. The selloff may not be done yet either. The prod? Amgen (NASDAQ:AMGN) is challenging Alexion's patent on Soliris, which is used to treat a trio of rare diseases. It makes up the bulk of Alexion's sales.It's an alarming development, although not one that's necessarily devastating. Right or wrong, running patent-based interference meant to disrupt other companies is the new norm within the pharmaceuticals arena, and there's not necessarily any assurance that Amgen will prevail. The chatter that Amgen could make an acquisition bid for Alexion still has its merits as well. * 10 Buy-and-Hold Stocks to Own Forever In the meantime, the forward-looking P/E of 9.9 suggests ALXN is priced cheaply enough to survive any profit-sharing agreement that Amgen may end up pursuing instead of an outright legal victory. Cigna (CI)While pharmacies and pharmaceuticals are certainly vulnerable to any sweeping overhauls in the way the United States healthcare industry works, it's not like the insurers are particularly well-shielded. Cigna (NYSE:CI), for instance, is down more than 30% since its early 2018 high on concerns about insurers' futures, after they all had a pretty good run between 2013 and 2017.Not everyone is concerned about one of a myriad of 'maybes' that could impact Cigna though.Alliance Bernstein analyst Lance Wilkes is one of those optimists. He recently upgraded CI stock while it was down, re-rating it at an "Outperform," explaining "We are increasing our price target and rating on [Cigna] based upon earnings growth driven from deal synergies and its low valuation, which we believe offset our [long term] concerns on policy risks and strategic position."CI stock is trading at only 14 times its trailing earnings, and only 8.2 times next year's expected profits. Eli Lilly (LLY)Source: Shutterstock Finally, add drugmaker Eli Lilly (NYSE:LLY) to your list of healthcare stocks to buy despite a recent wave of bad news.For Lilly, that's mostly been spurred by pipeline and portfolio questions. In March it announced it would launch a cheaper alternative to its own top-selling Humalog insulin, and early this year it decided to acquire Loxo Oncology at an unpopularly frothy premium.There's a reason that slide suffered during the first half of the year has started to reverse course beginning in early August. Not only did Lilly win the outcome it wanted in a recent arbitration claim regarding a collaboration it entered with Adocia to develop rapid-acting insulin, a phase 3 trial of its oral JAK inhibitor Baricitinib as a therapy for atopic dermatitis showed tremendous promise with last month's update.They're little victories that can really add up in investors' heads.As of this writing, James Brumley held no position in any of the aforementioned securities. You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks to Sell in Market-Cursed September * 7 of the Worst IPO Stocks in 2019 * 7 Best Stocks That Crushed It This Earnings Season The post 10 Healthcare Stocks to Buy Despite the Headlines appeared first on InvestorPlace.
- Zacks
Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties
Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.
- Zacks
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers
- Simply Wall St.
An Intrinsic Calculation For Johnson & Johnson (NYSE:JNJ) Suggests It's 43% Undervalued
How far off is Johnson & Johnson (NYSE:JNJ) from its intrinsic value? Using the most recent financial data, we'll take...
- Motley Fool
Here's Why Arrowhead Pharmaceuticals Rose 17.6% in August
The biopharma announced fiscal third-quarter 2019 operating results and multiple updates from the pipeline.
- Motley Fool
The 11 Biggest Dividend Stocks on the Market
Some of the biggest companies on earth are giving their investors a share of the profits each quarter through dividends.
- Zacks
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
Allergan (AGN) settles with two Ohio plaintiffs for $5 million. Merck's (MRK) Keytruda, Roche's (RHHBY) Tecentriq and J&J's (JNJ) Stelara get EU approval for expanded use.
- MarketWatch
Mallinckrodt’s suffers record plunge after report bankruptcy is being considered
Shares of Mallinckrodt PLC were suffered a record plunge to a record low Thursday, after a report that the specialty drug company had hired restructuring advisers and was considering bankruptcy ahead of federal opioid trials.
- Yahoo Finance Video
What's next for Purdue Pharma after filing for bankruptcy
Oxycontin maker Purdue Pharma filed for chapter 11 bankruptcy on Sunday, after reaching a tentative settlement with 24 states that accused the company of fueling the U.S. opioid crisis. Yahoo Finance's Alexis Keenan reports. William Soilman, Chairman and CEO of the Accreditation Council for Medical Affairs, further discusses with Yahoo Finance's Adam Shapiro and Julie Hyman.
- Yahoo Finance Video
Rep. McHenry says Trump is publicly saying what everybody privately grumbles about
President Trump attacking the Fed after the ECB cut rates by -0.5 percent. North Carolina Republican Rep. Patrick McHenry said "[Trump's] actually publicly saying what everybody privately grumbles about." He joins Yahoo Finance's Akiko Fujita.
